We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
McKesson (MCK - Free Report) ended the recent trading session at $705.45, demonstrating a -3.06% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.48%. Meanwhile, the Dow lost 0.02%, and the Nasdaq, a tech-heavy index, added 0.94%.
The stock of prescription drug distributor has risen by 1.8% in the past month, lagging the Medical sector's gain of 2.8% and the S&P 500's gain of 5.13%.
The investment community will be closely monitoring the performance of McKesson in its forthcoming earnings report. The company is scheduled to release its earnings on August 6, 2025. The company is forecasted to report an EPS of $8.33, showcasing a 5.71% upward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $95.77 billion, indicating a 20.79% increase compared to the same quarter of the previous year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $37.23 per share and a revenue of $405.85 billion, representing changes of +12.65% and +13.03%, respectively, from the prior year.
Any recent changes to analyst estimates for McKesson should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% higher. At present, McKesson boasts a Zacks Rank of #2 (Buy).
Looking at valuation, McKesson is presently trading at a Forward P/E ratio of 19.55. Its industry sports an average Forward P/E of 17.95, so one might conclude that McKesson is trading at a premium comparatively.
We can additionally observe that MCK currently boasts a PEG ratio of 1.45. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Dental Supplies industry was having an average PEG ratio of 1.68.
The Medical - Dental Supplies industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 23, which puts it in the top 10% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) Stock Falls Amid Market Uptick: What Investors Need to Know
McKesson (MCK - Free Report) ended the recent trading session at $705.45, demonstrating a -3.06% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.48%. Meanwhile, the Dow lost 0.02%, and the Nasdaq, a tech-heavy index, added 0.94%.
The stock of prescription drug distributor has risen by 1.8% in the past month, lagging the Medical sector's gain of 2.8% and the S&P 500's gain of 5.13%.
The investment community will be closely monitoring the performance of McKesson in its forthcoming earnings report. The company is scheduled to release its earnings on August 6, 2025. The company is forecasted to report an EPS of $8.33, showcasing a 5.71% upward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $95.77 billion, indicating a 20.79% increase compared to the same quarter of the previous year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $37.23 per share and a revenue of $405.85 billion, representing changes of +12.65% and +13.03%, respectively, from the prior year.
Any recent changes to analyst estimates for McKesson should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% higher. At present, McKesson boasts a Zacks Rank of #2 (Buy).
Looking at valuation, McKesson is presently trading at a Forward P/E ratio of 19.55. Its industry sports an average Forward P/E of 17.95, so one might conclude that McKesson is trading at a premium comparatively.
We can additionally observe that MCK currently boasts a PEG ratio of 1.45. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Dental Supplies industry was having an average PEG ratio of 1.68.
The Medical - Dental Supplies industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 23, which puts it in the top 10% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.